• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Puretech Health Plc ADR (NQ: PRTC )

    23.22 -1.10 (-4.52%)
    Streaming Delayed Price Updated: 10:43 AM EDT, Jul 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Puretech Health Plc ADR

    < Previous 1 2 3 4 5 Next >
    PureTech Health: Completion of Tender Offer & Total Voting Rights
    From PureTech Health plc
    Via Business Wire
    PureTech Health: Results of the Tender Offer
    From PureTech Health plc
    Via Business Wire
    PureTech Announces Change of Board Role
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team
    From PureTech Health plc
    Via Business Wire
    PureTech Health: Results of Annual General Meeting
    From PureTech Health plc
    Via Business Wire
    PureTech Health: Result of General Meeting
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company
    From PureTech Health plc
    Via Business Wire
    PureTech to Present at the Jefferies Global Healthcare Conference
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
    From PureTech Health plc
    Via Business Wire
    PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
    From PureTech Health plc
    Via Business Wire
    PureTech Announces Annual Results for Year Ended December 31, 2023
    From PureTech Health plc
    Via Business Wire
    PureTech Health: Notice of Results
    From PureTech Health plc
    Via Business Wire
    PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
    From PureTech Health plc
    Via Business Wire
    PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
    From PureTech Health plc 
    Via Business Wire
    PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
    From PureTech Health plc
    Via Business Wire
    PureTech Proposes $100 Million Capital Return
    From PureTech Health plc
    Via Business Wire
    Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
    From PureTech Health plc
    Via Business Wire
    PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
    From PureTech Health plc
    Via Business Wire
    PureTech to Present at Two Upcoming Investor Conferences
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
    From PureTech Health plc
    Via Business Wire
    PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
    From PureTech Health plc
    Via Business Wire
    PureTech Year End Update and Outlook for 2024
    From PureTech Health plc
    Via Business Wire
    PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
    From PureTech Health plc
    Via Business Wire
    PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
    From PureTech Health plc
    Via Business Wire
    PureTech to Present at Two Upcoming Investor Conferences
    From PureTech Health plc
    Via Business Wire
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.